Department of Breast Surgery, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian 350001, P.R. China.
Department of Surgical Laboratory, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian 350001, P.R. China.
Mol Med Rep. 2019 May;19(5):4344-4352. doi: 10.3892/mmr.2019.10100. Epub 2019 Mar 28.
Breast cancer (BC) is the most frequently diagnosed type of cancer and the leading cause of cancer‑associated mortality among women worldwide. However, the molecular basis for the pathogenesis of BC requires further exploration. Recent studies have demonstrated that chaperonin‑containing TCP1 subunit 6A (CCT6A) efficiently suppresses transforming growth factor‑β‑mediated metastasis by inhibiting the function of SMAD family member 2 in lung cancer. However, the functional significance of CCT6A in other types of cancer, including BC, remains to be investigated. Therefore, this study evaluated CCT6A expression in BC samples, and further analysed its association with survival, clinicopathological parameters and related signalling pathways using online datasets. The present study indicated that CCT6A expression was significantly higher in BC tissues compared with in surrounding noncancerous tissues at both mRNA and protein levels. Furthermore, increased CCT6A expression was significantly associated with poor survival, including overall survival, relapse‑free survival, distant metastasis‑free survival and post progression survival, in patients with BC. Pathway finder analysis indicated that CCT6A was significantly associated with the cell cycle, and its expression was significantly positively correlated with cyclin (CCN)B2 and CCNA2 expression. Taken together, to the best of our knowledge, the present study is the first to indicate that CCT6A may serve a significant role in BC tumour progression.
乳腺癌 (BC) 是全球最常见的癌症类型，也是女性癌症相关死亡的主要原因。然而，BC 发病机制的分子基础仍需要进一步探索。最近的研究表明，热休克蛋白 10 家族成员 6A (CCT6A) 可通过抑制肺癌中 SMAD 家族成员 2 的功能，有效抑制转化生长因子-β介导的转移。然而，CCT6A 在其他类型的癌症中的功能意义，包括 BC，仍需要研究。因此，本研究评估了 CCT6A 在 BC 样本中的表达，并进一步使用在线数据集分析了其与生存、临床病理参数和相关信号通路的关联。本研究表明，CCT6A 在 BC 组织中的表达在 mRNA 和蛋白水平上均显著高于周围非癌组织。此外，CCT6A 表达增加与 BC 患者的不良生存显著相关，包括总生存、无复发生存、无远处转移生存和无进展生存。途径发现分析表明，CCT6A 与细胞周期显著相关，其表达与细胞周期蛋白 B2 (CCNB2) 和细胞周期蛋白 A2 (CCNA2) 的表达呈显著正相关。综上所述，据我们所知，本研究首次表明 CCT6A 可能在 BC 肿瘤进展中发挥重要作用。
